首页 > 资讯    /    正文

Sinovac Amends Shareholder Rights Plan

Sinovac Biotech Ltd. (“Sinovac” or the “Company”) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today announced that its board of directors has amended its shareholder rights plan. The amendment extends the expiration date of the plan from February 22, 2024 to February 22, 2025.

About SINOVAC

Sinovac Biotech Ltd. (SINOVAC) is a China-based biopharmaceutical company that focuses on the R&D, manufacturing, and commercialization of biomedical products that protect against human infectious diseases.

SINOVAC’s product portfolio includes vaccines against COVID-19, enterovirus 71 (EV71) infected hand-foot-mouth disease (HFMD), hepatitis A, varicella, influenza, poliomyelitis, pneumococcal disease, mumps, etc.

The COVID-19 vaccine, CoronaVac®, has been approved for use in more than 60 countries and regions worldwide. The hepatitis A vaccine, Healive®, passed WHO prequalification requirements in 2017. The EV71 vaccine, Inlive®, is an innovative vaccine under "Category 1 Preventative Biological Products" and commercialized in China in 2016. In 2022, SINOVAC’s Sabin-strain inactivated polio vaccine (sIPV) and varicella vaccine were prequalified by the WHO.

SINOVAC was the first company to be granted approval for its H1N1 influenza vaccine Panflu.1®, which has supplied the Chinese government's vaccination campaign and stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine, Panflu®, to the Chinese government stockpiling program.

SINOVAC continually dedicates itself to pipeline development including but not limited to new technology, new vaccines as well as other biomedical products. We will constantly explore global opportunities of strategic expansion.

最新文章

休斯顿大学视光学院Mark A.Bullimore教授:儿童青少年近视防控,每一个屈光度都重要 杭州天目山医院耳鼻喉科:精准诊疗,守护呼吸与听觉的“门户” 坚守人民立场,用电影阐述生生不息的人民史诗——康红立导演如何用真情丈量人民足迹,用电影弘扬时代精神 ​深圳网站建设公司甄选指南:368 家上市公司首选沙漠风的深度解密 聚焦游戏测试、副玩法和AI驱动,Meta赋能游戏出海增长新纪元 威雅学校:2025年秋季学期新生招生简章

Copyright © 2024 商圈 All Rights Reserved.

本站部分内容来源于用户投稿,内容相关Q:230098551